Dermatology: clinical-trial pipeline
16,658 dermatology trials are in ClinicalTrials.gov and the EU CTIS portal; 3,364 are not yet finished and 387 of those are in phase 2/3 or 3. Source: Arcadium Data, data as of .
Open trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 1,895 |
| Phase 2 | 453 |
| Phase 3 | 331 |
| Phase 1 | 224 |
| Phase 4 | 206 |
| Phase 1/2 | 119 |
| Early phase 1 | 80 |
| Phase 2/3 | 56 |
Sponsors with the most open trials
Recently changed open trials
| Registry id | Title | Sponsor | Phase | Status | Countries |
|---|---|---|---|---|---|
| NCT06220604 | A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-AD… | Janssen Research & Development, LLC | Phase 3 | Active, not recruiting | Australia, Brazil, Canada, Germany +8 |
| NCT06100744 | A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Chil… | AbbVie | Phase 3 | Not yet recruiting | Australia, Canada, Germany, Spain +5 |
| NCT06012240 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants… | AbbVie | Phase 3 | Recruiting | Argentina, Australia, Belgium, Bulgaria +23 |
| NCT06118411 | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Parti… | AbbVie | Phase 3 | Active, not recruiting | Argentina, Belgium, Bulgaria, Canada +15 |
| NCT06113471 | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) | Incyte Corporation | Phase 3 | Active, not recruiting | Bulgaria, Canada, Germany, France +5 |
| NCT06072183 | A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranq… | Pfizer | Phase 3 | Active, not recruiting | Australia, Belgium, Bulgaria, Canada +13 |
| NCT03582800 | Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study | University Hospital, Limoges | Phase 2 | Recruiting | France |
| 2023-505017-25-02 | Treatment of difficult-to-heal wounds with stem cells included in a gel consistency dressing | Fundacion Para La Investigacion Y La Innovacion Biosanitaria Del Principado De Asturias | Phase 1/2 | Recruiting | Spain |
| NCT06113445 | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) | Incyte Corporation | Phase 3 | Active, not recruiting | Belgium, Canada, Germany, Spain +6 |
| 2023-510297-14-00 | Safety and efficacy of low-dose interleukin-2 therapy in chronic inflammatory barrier diseases (IL-2-ID): a s… | Universitaetsklinikum Schleswig-Holstein AöR | Phase 2 | Recruiting | Germany |
| 2023-504552-10-01 | Double-blind, randomised clinical study comparing efficacy and safety of Clindamycin/Tretinoin Gel (10 mg/g +… | Dermapharm AG | Phase 3 | Recruiting | Germany |
| NCT06136741 | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-S… | Nektar Therapeutics | Phase 2 | Active, not recruiting | Australia, Bulgaria, Canada, Czechia +6 |
| NCT06109649 | A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-U… | Clinuvel, Inc. | Phase 3 | Not yet recruiting | France, United Kingdom, Italy, Kenya +1 |
| NCT06651151 | NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma | Oslo University Hospital | Phase 2 | Recruiting | Norway |
| NCT06163326 | A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitil… | Pfizer | Phase 3 | Not yet recruiting | Australia, Bulgaria, Canada, China +9 |
| NCT06073132 | An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study… | TWi Biotechnology, Inc. | Phase 2/3 | Active, not recruiting | United Arab Emirates, Austria, Australia, Belgium +15 |
| NCT04929210 | A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis A… | Janssen Research & Development, LLC | Phase 4 | Active, not recruiting | Argentina, Australia, Bulgaria, Canada +21 |
| NCT06526182 | A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis | Almirall, S.A. | Phase 3 | Active, not recruiting | Austria, Denmark, Spain, France +2 |
| NCT06212999 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe… | Incyte Corporation | Phase 3 | Active, not recruiting | Austria, Australia, Belgium, Bulgaria +13 |
| NCT04588311 | ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients | Australian and New Zealand Intensive Care Research Centre | Phase 3 | Recruiting | Australia, Belgium, Switzerland, Germany +6 |
All areas: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Dermatology clinical trials: 3,364 open, 387 in phase 3", https://arcadiumdata.io/clinical-trials/area/dermatology/, data as of 2026-10-25.